Related Experiment Video
Updated: Aug 1, 2025

Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis
Published on: February 3, 2022
Targeting mitochondrial dynamics by AZD5363 in triple-negative breast cancer MDA-MB-231 cell-derived spheres
Yingqiang Fu1, Wei Dong1, Yuting Xu1
1Department of Breast Cancer Surgery, Harbin Medical University Cancer Hospital, Harbin Medical University, Haping RD NO, 150086, Harbin, Heilongjiang Province, People's Republic of China.
Abstract:
Breast cancer stem cells (BCSCs) have been suggested to contribute to chemotherapeutic resistance and disease relapse in breast cancer. Thus, BCSCs represent a promising target in developing novel breast cancer treatment strategies. Mitochondrial dynamics in BCSCs were recently highlighted as an available approach for targeting BCSCs. In this study, a three-dimensional (3D) cultured breast cancer stem cell spheres model was constructed. Mitochondrial dynamics and functions were analyzed by flow cytometry and confocal microscopy. We have demonstrated that the protein levels of FIS 1 and Mitofusin 1 were significantly increased in BCSCs. Moreover, Capivasertib (AZD5363) administration could suppress Mitofusin1 expression in BCSCs. Our use of MitoTracker Orange and annexin V double-staining assay suggested that AZD5363 could induce apoptosis in BCSCs. The sensitivity of stem cell spheres to doxorubicin was investigated by CCK8 assay, and our results indicated that AZD5363 could re-sensitize BCSCs to Doxo. Flow cytometry analysis identified doxo-induced CD44 and CD133 expression in BCSCs could be suppressed by AZD5363. In combination with AZD536, doxo-induced apoptosis in the BCSCs was significantly increased. In conclusion, our study explored, for the first time, that AZD5363 could target mitochondrial dynamics in 3D cultured stem cell spheres (BCSCs) by regulating Mitofusin.
Insights
Capivasertib (AZD5363) targets mitochondrial dynamics in breast cancer stem cells (BCSCs), enhancing chemotherapy effectiveness. This approach shows promise for overcoming treatment resistance and preventing disease relapse in breast cancer patients.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Breast cancer stem cells (BCSCs) are implicated in therapeutic resistance and relapse.
- Targeting BCSCs is crucial for developing effective breast cancer treatments.
- Mitochondrial dynamics present a novel strategy for targeting BCSCs.
Purpose of the Study:
- To investigate the role of mitochondrial dynamics in BCSCs.
- To evaluate Capivasertib (AZD5363) as a therapeutic agent targeting BCSCs.
- To assess AZD5363's ability to re-sensitize BCSCs to chemotherapy.
Main Methods:
- Established a 3D cultured breast cancer stem cell spheres model.
- Analyzed mitochondrial dynamics and protein expression using flow cytometry and confocal microscopy.
- Assessed apoptosis and chemotherapy sensitivity via MitoTracker Orange, annexin V, and CCK8 assays.
Main Results:
- FIS 1 and Mitofusin 1 protein levels were elevated in BCSCs.
- AZD5363 suppressed Mitofusin 1 expression and induced apoptosis in BCSCs.
- AZD5363 re-sensitized BCSCs to doxorubicin, suppressed doxorubicin-induced CD44/CD133 expression, and enhanced doxorubicin-induced apoptosis.
Conclusions:
- AZD5363 effectively targets mitochondrial dynamics in 3D cultured BCSCs by regulating Mitofusin.
- AZD5363 demonstrates potential in overcoming chemotherapy resistance in breast cancer.
- This study provides a novel therapeutic strategy for breast cancer treatment by targeting BCSCs.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Drugs that Destabilize Microtubules
Drugs that Stabilize Microtubules

